RARA and acute myeloid leukemia: FTO, an m6A eraser, promotes leukemic oncogene-mediated cell transformation and leukemogenesis, and suppresses all-trans-retinoic acid (ATRA)-triggered AML cell differentiation by regulating the expression of specific target genes, including ankyrin repeat and SOCS box-containing 2 (ASB2) and retinoic acid receptor a (RARA), through repressing m6A levels in these transcripts [153].